Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
复制标题
用于生物经验的急性严重溃疡性结肠炎患者的tofacitib：一项回顾性病例对照研究。
DOI：
10.1016/j.cgh.2021.05.038
复制
发表时间：
2021-10
期刊：
影响因子：
--
通讯作者：
Higgins PDR
中科院分区：
文献类型：
--
作者：
Berinstein JA;Sheehan JL;Dias M;Berinstein EM;Steiner CA;Johnson LA;Regal RE;Allen JI;Cushing KC;Stidham RW;Bishu S;Kinnucan JAR;Cohen-Mekelburg SA;Waljee AK;Higgins PDR
Despite rescue therapy, more than 30% of patients with acute severe ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting JAK inhibitor with proven efficacy in ulcerative colitis. Tofacitinib may provide additional means for preventing colectomy in patients with ASUC. A retrospective case-control study was performed evaluating the efficacy of tofacitinib induction in biologic-experienced patients admitted with ASUC requiring IV corticosteroids. Tofacitinib patients were matched 1:3 to controls according to gender and date of admission. Using Cox regression adjusted for disease severity, we estimated the 90-day risk of colectomy. Rates of complications and steroid dependence were examined as secondary outcomes. Forty patients who received tofacitinib were matched 1:3 to controls (n=113). Tofacitinib was protective against colectomy at 90 days compared to matched controls (HR 0.28, 95% CI 0.10, 0.81, P = 0.018). When stratifying according to treatment dose, 10mg three times daily (HR 0.11 95% CI 0.02, 0.56, P=0.008) was protective, while 10mg twice daily was not significantly protective (HR 0.66, 95% CI 0.21, 2.09, P=0.5). Rate of complications and steroid dependence were similar between tofacitinib and controls. Tofacitinib with concomitant IV corticosteroids may be an effective induction strategy in biologic-experienced patients hospitalized with ASUC. Prospective trials are needed to identify the safety, optimal dose, frequency, and duration of tofacitinib for ASUC.
登录
查看更多内容
影响因子：
24.5
作者：
Travis, SPL;Farrant, JM;Ricketts, C
通讯作者：
Ricketts, C
DOI：
10.1016/j.cgh.2020.03.072
发表时间：
2021-03
期刊：
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子：
--
作者：
Battat R;Hemperly A;Truong S;Whitmire N;Boland BS;Dulai PS;Holmer AK;Nguyen NH;Singh S;Vande Casteele N;Sandborn WJ
通讯作者：
Sandborn WJ
影响因子：
12.6
作者：
Hanauer, Stephen;Panaccione, Remo;Su, Chinyu
通讯作者：
Su, Chinyu
DOI：
10.1136/bmj.j1415
发表时间：
2017-04-12
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Waljee AK;Rogers MA;Lin P;Singal AG;Stein JD;Marks RM;Ayanian JZ;Nallamothu BK
通讯作者：
Nallamothu BK
影响因子：
158.5
作者：
Sandborn, William J.;Ghosh, Subrata;Niezychowski, Wojciech
通讯作者：
Niezychowski, Wojciech